Are Osteoclasts Needed for the Bone Anabolic Response to Parathyroid Hormone?: A STUDY OF INTERMITTENT PARATHYROID HORMONE WITH DENOSUMAB OR ALENDRONATE IN KNOCK-IN MICE EXPRESSING HUMANIZED RANKL*
Open Access
- 3 September 2010
- journal article
- Published by Elsevier BV in Journal of Biological Chemistry
- Vol. 285 (36), 28164-28173
- https://doi.org/10.1074/jbc.m110.101964
Abstract
PTH stimulates osteoblastic cells to form new bone and to produce osteoblast-osteoclast coupling factors such as RANKL. Whether osteoclasts or their activity are needed for PTH anabolism remains uncertain. We treated ovariectomized huRANKL knock-in mice with a human RANKL inhibitor denosumab (DMAb), alendronate (Aln), or vehicle for 4 weeks, followed by co-treatment with intermittent PTH for 4 weeks. Loss of bone mass and microarchitecture was prevented by Aln and further significantly improved by DMAb. PTH improved bone mass, microstructure, and strength, and was additive to Aln but not to DMAb. Aln inhibited biochemical and histomorphometrical indices of bone turnover,--i.e. osteocalcin and bone formation rate (BFR) on cancellous bone surfaces-, and Dmab inhibited them further. However Aln increased whereas Dmab suppressed osteoclast number and surfaces. PTH significantly increased osteocalcin and bone formation indices, in the absence or presence of either antiresorptive, although BFR remained lower in presence of Dmab. To further evaluate PTH effects in the complete absence of osteoclasts, high dose PTH was administered to RANK(-/-) mice. PTH increased osteocalcin similarly in RANK(-/-) and WT mice. It also increased BMD in RANK(-/-) mice, although less than in WT. These results further indicate that osteoclasts are not strictly required for PTH anabolism, which presumably still occurs via stimulation of modeling-based bone formation. However the magnitude of PTH anabolic effects on the skeleton, in particular its additive effects with antiresorptives, depends on the extent of the remodeling space, as determined by the number and activity of osteoclasts on bone surfaces.Keywords
This publication has 47 references indexed in Scilit:
- Osteoprotegerin Abrogated Cortical Porosity and Bone Marrow Fibrosis in a Mouse Model of Constitutive Activation of the PTH/PTHrP ReceptorThe American Journal of Pathology, 2009
- β-Arrestin2 Regulates RANKL and Ephrins Gene Expression in Response to Bone Remodeling in MiceJournal of Bone and Mineral Research, 2009
- Giant Osteoclast Formation and Long-Term Oral Bisphosphonate TherapyNew England Journal of Medicine, 2009
- Parathyroid hormone treatment for osteoporosisCurrent Opinion in Endocrinology, Diabetes and Obesity, 2008
- EphrinB2 Regulation by PTH and PTHrP Revealed by Molecular Profiling in Differentiating OsteoblastsJournal of Bone and Mineral Research, 2008
- Effects of daily treatment with parathyroid hormone 1–84 for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeysBone, 2007
- Co-Treatment of PTH With Osteoprotegerin or Alendronate Increases Its Anabolic Effect on the Skeleton of Oophorectomized MiceJournal of Bone and Mineral Research, 2007
- Osteoclast-derived activity in the coupling of bone formation to resorptionTrends in Molecular Medicine, 2005
- OPG and PTH-(1-34) Have Additive Effects on Bone Density and Mechanical Strength in Osteopenic Ovariectomized RatsEndocrinology, 2001
- On the Mechanism of Cancellous Bone Preservation in Postmenopausal Women with Mild Primary HyperparathyroidismJournal of Clinical Endocrinology & Metabolism, 1999